Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lorieta Leppin"'
Autor:
Thomas Bukur, Eileen Powalsky, Martin Suchan, Mustafa Diken, Marta Faryna, Lena M. Kranz, Christian Albrecht, Ugur Sahin, Barbara Schrörs, Rainer Hipfel, Özlem Türeci, Lorieta Leppin
Publikováno v:
Cancer Immunology Research. 8:B62-B62
Identification of biomarkers is pivotal towards the proper development of cancer immunotherapies, in particular for designing the most effective regimens and identifying patient subgroups most likely to benefit from a given treatment. T-cell receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2674ee0df95aae77896b7aad238a37cd
https://doi.org/10.1158/2326-6074.tumimm18-b62
https://doi.org/10.1158/2326-6074.tumimm18-b62
Autor:
Karena Kosco, Filip Janku, Lorieta Leppin, Patrick P. Lin, Razelle Kurzrock, Latifa Hassaine, Jason C. Poole, Cecile Rose T. Vibat, Mark Erlander, Funda Meric-Bernstam, Vanda M. Stepanek, Veronica R. Holley, Goran Cabrilo
Publikováno v:
Oncotarget
Oncotarget, vol 5, iss 11
Oncotarget, vol 5, iss 11
Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF V600E mutation (>50% of patients). Patients with BRAF-mutant ECD can respond to BRAF inhibitors. Unfortunately, the lack of adequate archival tissue often precludes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8651ec88ad797a3f4d3c08dd55d3b22a
https://doi.org/10.18632/oncotarget.1964
https://doi.org/10.18632/oncotarget.1964
Autor:
Ralph Zinner, Latifa Hassaine, Filip Janku, Lorieta Leppin, Karena Kosco, Gerald S. Falchook, Funda Meric-Bernstam, Rajyalakshmi Luthra, Vivek Subbiah, Siqing Fu, Sarina Anne Piha-Paul, Cecile Rose T. Vibat, David S. Hong, Jennifer J. Wheler, Veronica R. Holley, Mark G. Erlander, Jason C. Poole, Aung Naing, Daniel D. Karp, Vanda M. Stepanek
Publikováno v:
Cancer Research. 74:LB-170
Background: Detection and monitoring of oncogenic mutations in cell-free urinary DNA opens the possibility of a new paradigm for a truly non-invasive method of individualized care for metastatic cancer patients, which would enable the quantitation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f9c410708460c9fbd33f425a737fcb4
https://doi.org/10.1158/1538-7445.am2014-lb-170
https://doi.org/10.1158/1538-7445.am2014-lb-170
Autor:
Sarina Anne Piha-Paul, Lorieta Leppin, Rajyalakshmi Luthra, Vivek Subbiah, Aung Naing, Vanda M. Stepanek, Cecile Rose T. Vibat, Mark G. Erlander, Karena Kosco, Filip Janku, Latifa Hassaine, Funda Meric-Bernstam, Jennifer J. Wheler, Veronica R. Holley, Goran Cabrilo, Gerald S. Falchook
Publikováno v:
Journal of Clinical Oncology. 32:e22175-e22175
e22175 Background: Detection and monitoring of oncogenic mutations in urinary cell-free (cf) DNA opens the possibility of a new paradigm for a truly non-invasive method of individualized care for m...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4f84496f22ace857408d06c7157e129
https://doi.org/10.1200/jco.2014.32.15_suppl.e22175
https://doi.org/10.1200/jco.2014.32.15_suppl.e22175
Autor:
Mikhail S. Shchepinov, Charles P. Rodi, Mikhail F. Denissenko, Kevin J. Smylie, Ralf Worl, Charles R. Cantor, A. Lorieta Leppin
Chemical and enzymatic approaches were used to produce polynucleotide fragments containing acid-labile internucleotide P3′-N5′ phosphoramidate bonds, either in a surface-bound form or in solution. The primer extension reaction utilizing 5′-amin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6d86b50549bccb6a3ca85d71501f9dc
https://europepmc.org/articles/PMC55906/
https://europepmc.org/articles/PMC55906/
Autor:
Filip Janku, Karena Kosco, Lafifa Hassaine, Jason C. Poole, R. Luthra, Jennifer J. Wheler, Mark G. Erlander, Funda Meric-Bernstam, Veronica R. Holley, Lorieta Leppin
Publikováno v:
Molecular Cancer Therapeutics. 12:B177-B177
Background: Previous studies have demonstrated the ability to detect tumor DNA mutations by PCR methodologies within cell-free urinary DNA in metastatic cancer patients. This has opened up the possibility to use massively parallel deep sequencing app
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da104255b3e6444436ce5d7dbb65e722
https://doi.org/10.1158/1535-7163.targ-13-b177
https://doi.org/10.1158/1535-7163.targ-13-b177
Autor:
Funda Meric-Bernstam, Jennifer J. Wheler, Aung Naing, Lorieta Leppin, Karena Kosco, Mark G. Erlander, R. Luthra, Daniel D. Karp, Ralph Zinner, Gerald S. Falchook, Jason C. Poole, Latifa Hassaine, Veronica R. Holley, David S. Hong, Vanda M. Stepanek, Siqing Fu, Sarina Anne Piha-Paul, Apostolia Maria Tsimberidou, Filip Janku
Publikováno v:
Molecular Cancer Therapeutics. 12:B175-B175
Background: Detection and monitoring of oncogenic mutations in cell-free urinary DNA opens the possibility of a new paradigm for a truly non-invasive method of individualized care for metastatic cancer patients, enabling the quantitation of mutationa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7097498ac814f692707368fb8f051610
https://doi.org/10.1158/1535-7163.targ-13-b175
https://doi.org/10.1158/1535-7163.targ-13-b175